Skip to main content
AMPH logo

AMPH

Amphastar Pharmaceuticals, Inc.
$20.08 +0.47 (+2.40%) At close · Jul 7
Market Cap
$826.74M
Shares
44,092,919

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$719.89M -1.7%
FY2025 Revenue FY2012–FY2025
Net Income
$98.09M -38.5%
FY2025 Net Income FY2012–FY2025
Gross Margin
49.46% -1.6pp
FY2025 Gross Margin FY2012–FY2025
Operating Margin
19.5% -8.6pp
FY2025 Operating Margin FY2012–FY2025
Diluted EPS
$2.03 -33.7%
FY2025 Diluted EPS FY2012–FY2025
Operating Cash Flow
$156.12M -26.8%
FY2025 Operating Cash Flow FY2012–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
$720.53M $719.89M $731.97M $644.4M $498.99M $437.77M $349.85M $322.36M $294.67M $240.18M $255.17M $251.52M $210.46M $229.68M $204.32M
$379.4M $363.83M $358.11M $293.27M $250.13M $238.03M $206.51M $190.43M $187.68M $149.67M $150.97M $174.17M $159.21M $142.73M $114.02M
$341.13M $356.06M $373.86M $351.12M $248.86M $199.74M $143.34M $131.92M $106.99M $90.51M $104.2M $77.35M $51.26M $86.96M $90.3M
49.46% 51.08% 54.49% 49.87% 45.63% 40.97% 40.92% 36.31% 37.68% 40.83% 30.75% 24.35% 37.86% 44.2%
$92.49M $85.84M $73.91M $73.74M $74.77M $60.93M $67.23M $68.85M $57.56M $43.5M $41.52M $37.27M $28.87M $33.02M $31.16M
$43.95M $43.89M $37.8M $28.85M $21.53M $17.49M $14.78M $12.83M $8.16M $6.46M $5.47M $5.47M $5.56M $5.35M $4.43M
$87.96M $85.93M $56.72M $51.54M $45.06M $51.43M $50.38M $50.28M $49.89M $44.46M $41.83M $41.5M $34.81M $30.97M $27.22M
$25.05M $24.72M $12.83M $954K $1.07M $1.04M $1.04M $1.99M $2.86M $2.52M $1.94M $1.92M $1.91M $1.84M
$25.74M $12.6M $10.23M $9.03M $7.06M $6.05M $6.42M
$224.39M $215.65M $168.44M $154.13M $141.36M $129.85M $132.39M $131.96M $115.61M $91.78M $88.82M $84.25M $69.24M $69.47M $64.91M
$116.74M $140.4M $205.42M $196.99M $107.5M $69.89M $10.95M -$39K -$8.62M -$1.27M $15.38M -$6.9M -$17.98M $17.49M $25.4M
19.5% 28.06% 30.57% 21.54% 15.96% 3.13% -0.01% -2.93% -0.53% 6.03% -2.74% -8.54% 7.61% 12.43%
$222.72M $120.09M $80.11M $19.98M $7.02M -$2.57M $5.15M
$25.75M $25.48M $30.34M $27.16M $1.85M $885K $374K $119K $243K $826K $1.02M $987K $609K $958K $784K
$8.99M $8.68M $10.61M $5.46M $1.32M $601K $642K $997K $456K $425K $270K $315K $243K $187K $242K
-$13.93M -$16.78M -$15.66M -$25.63M $8.54M $14.25M -$6.32M $60.27M -$1.3M $2.52M -$746K -$3.47M -$165K -$263K $481K
-$573K -$1.98M -$1.18M -$208K
$102.81M $123.62M $189.76M $171.36M $116.04M $84.14M $4.64M $60.23M -$9.93M $1.25M $14.63M -$10.36M -$18.15M $17.23M $25.88M
$23.59M $25.53M $29.67M $31.83M $23.48M $20.63M $3.54M $13.72M -$3.27M -$2.4M $4.81M -$7.58M -$7.45M $5.37M $7.78M
$79.23M $98.09M $159.52M $137.55M $91.39M $62.12M $1.4M $48.94M -$5.74M $3.65M $9.82M -$2.79M -$10.7M $11.86M $18.09M
13.63% 21.79% 21.34% 18.31% 14.19% 0.4% 15.18% -1.95% 1.52% 3.85% -1.11% -5.08% 5.16% 8.86%
$1.19M -$306K -$2.43M -$922K
$81.46M $101.96M $158.82M $137.69M $89.53M $59.07M $2.37M $48.27M -$7.65M $6.24M $7.6M -$3.61M -$12.35M $11.86M
USD/shares $2.10 $3.29 $2.85 $1.88 $1.30 $0.03 $1.04 -$0.12 $0.08 $0.22 -$0.06 -$0.25 $0.31 $0.47
USD/shares $2.03 $3.06 $2.60 $1.74 $1.25 $0.03 $0.98 -$0.12 $0.08 $0.21 -$0.06 -$0.25 $0.31 $0.46
shares 46.74M 48.43M 48.27M 48.55M 47.78M 47.04M 46.98M 46.4M 46.11M 45.38M 44.96M 41.96M 38.71M 38.58M
shares 48.22M 52.06M 53M 52.43M 49.78M 49.12M 49.91M 46.4M 48.37M 47.5M 44.96M 41.96M 38.88M 38.94M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $411.61M in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
EV/EBIT
P/E (TTM)
11.30×
Drug Manufacturers - Specialty & Generic median 21.44×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Pharmaceutical Products Segment $719,887,000 $731,967,000 $644,395,000 $498,987,000
Active Pharmaceutical Ingredient Segment $18,198,000 $18,478,000 $20,357,000 $23,607,000
Finished Pharmaceutical Products Segment $419,570,000 $331,368,000 $302,000,000 $271,059,000

By Geography (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
United States $681,422,000 $707,681,000 $635,192,000 $486,833,000 $419,869,000 $333,093,000 $304,896,000 $279,122,000
France $35,281,000 $19,947,000 $4,698,000 $7,457,000 $11,879,000 $13,592,000 $15,980,000 $15,544,000
China $3,184,000 $4,339,000 $4,505,000 $4,697,000 $6,020,000 $3,161,000 $1,481,000

By Product & Service (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Product $719,887,000 $712,814,000 $593,238,000 $498,987,000 $437,768,000
Product And Service Other $19,153,000 $51,157,000
Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 7 filings 6 filers Visit website Investor relations